Cargando…

Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]

INTRODUCTION: This prospective randomized clinical study investigated the efficacy and safety of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 (7.2% NaCl/HES 200/0.5) in comparison with 15% mannitol in the treatment of increased intracranial pressure (ICP). METHODS: Forty neurosurgical patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Harutjunyan, Lilit, Holz, Carsten, Rieger, Andreas, Menzel, Matthias, Grond, Stefan, Soukup, Jens
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297608/
https://www.ncbi.nlm.nih.gov/pubmed/16277715
http://dx.doi.org/10.1186/cc3767
_version_ 1782126230253862912
author Harutjunyan, Lilit
Holz, Carsten
Rieger, Andreas
Menzel, Matthias
Grond, Stefan
Soukup, Jens
author_facet Harutjunyan, Lilit
Holz, Carsten
Rieger, Andreas
Menzel, Matthias
Grond, Stefan
Soukup, Jens
author_sort Harutjunyan, Lilit
collection PubMed
description INTRODUCTION: This prospective randomized clinical study investigated the efficacy and safety of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 (7.2% NaCl/HES 200/0.5) in comparison with 15% mannitol in the treatment of increased intracranial pressure (ICP). METHODS: Forty neurosurgical patients at risk of increased ICP were randomized to receive either 7.2% NaCl/HES 200/0.5 or 15% mannitol at a defined infusion rate, which was stopped when ICP was < 15 mmHg. RESULTS: Of the 40 patients, 17 patients received 7.2% NaCl/HES 200/0.5 and 15 received mannitol 15%. In eight patients, ICP did not exceed 20 mmHg so treatment was not necessary. Both drugs decreased ICP below 15 mmHg (p < 0.0001); 7.2% NaCl/HES 200/0.5 within 6.0 (1.2–15.0) min (all results are presented as median (minimum-maximum range)) and mannitol within 8.7 (4.2–19.9) min (p < 0.0002). 7.2% NaCl/HES 200/0.5 caused a greater decrease in ICP than mannitol (57% vs 48%; p < 0.01). The cerebral perfusion pressure was increased from 60 (39–78) mmHg to 72 (54–85) mmHg by infusion with 7.2% NaCl/HES 200/0.5 (p < 0.0001) and from 61 (47–71) mmHg to 70 (50–79) mmHg with mannitol (p < 0.0001). The mean arterial pressure was increased by 3.7% during the infusion of 7.2% NaCl/HES 200/0.5 but was not altered by mannitol. There were no clinically relevant effects on electrolyte concentrations and osmolarity in the blood. The mean effective dose to achieve an ICP below 15 mmHg was 1.4 (0.3–3.1) ml/kg for 7.2% NaCl/HES 200/0.5 and 1.8 (0.45–6.5) ml/kg for mannitol (p < 0.05). CONCLUSION: 7.2% NaCl/HES 200/0.5 is more effective than mannitol 15% in the treatment of increased ICP. A dose of 1.4 ml/kg of 7.2% NaCl/HES 200/0.5 can be recommended as effective and safe. The advantage of 7.2% NaCl/HES 200/0.5 might be explained by local osmotic effects, because there were no clinically relevant differences in hemodynamic clinical chemistry parameters.
format Text
id pubmed-1297608
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12976082005-12-01 Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180] Harutjunyan, Lilit Holz, Carsten Rieger, Andreas Menzel, Matthias Grond, Stefan Soukup, Jens Crit Care Research INTRODUCTION: This prospective randomized clinical study investigated the efficacy and safety of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 (7.2% NaCl/HES 200/0.5) in comparison with 15% mannitol in the treatment of increased intracranial pressure (ICP). METHODS: Forty neurosurgical patients at risk of increased ICP were randomized to receive either 7.2% NaCl/HES 200/0.5 or 15% mannitol at a defined infusion rate, which was stopped when ICP was < 15 mmHg. RESULTS: Of the 40 patients, 17 patients received 7.2% NaCl/HES 200/0.5 and 15 received mannitol 15%. In eight patients, ICP did not exceed 20 mmHg so treatment was not necessary. Both drugs decreased ICP below 15 mmHg (p < 0.0001); 7.2% NaCl/HES 200/0.5 within 6.0 (1.2–15.0) min (all results are presented as median (minimum-maximum range)) and mannitol within 8.7 (4.2–19.9) min (p < 0.0002). 7.2% NaCl/HES 200/0.5 caused a greater decrease in ICP than mannitol (57% vs 48%; p < 0.01). The cerebral perfusion pressure was increased from 60 (39–78) mmHg to 72 (54–85) mmHg by infusion with 7.2% NaCl/HES 200/0.5 (p < 0.0001) and from 61 (47–71) mmHg to 70 (50–79) mmHg with mannitol (p < 0.0001). The mean arterial pressure was increased by 3.7% during the infusion of 7.2% NaCl/HES 200/0.5 but was not altered by mannitol. There were no clinically relevant effects on electrolyte concentrations and osmolarity in the blood. The mean effective dose to achieve an ICP below 15 mmHg was 1.4 (0.3–3.1) ml/kg for 7.2% NaCl/HES 200/0.5 and 1.8 (0.45–6.5) ml/kg for mannitol (p < 0.05). CONCLUSION: 7.2% NaCl/HES 200/0.5 is more effective than mannitol 15% in the treatment of increased ICP. A dose of 1.4 ml/kg of 7.2% NaCl/HES 200/0.5 can be recommended as effective and safe. The advantage of 7.2% NaCl/HES 200/0.5 might be explained by local osmotic effects, because there were no clinically relevant differences in hemodynamic clinical chemistry parameters. BioMed Central 2005 2005-08-09 /pmc/articles/PMC1297608/ /pubmed/16277715 http://dx.doi.org/10.1186/cc3767 Text en Copyright © 2005 Harutjunya et al.; licensee BioMed Central Ltd.
spellingShingle Research
Harutjunyan, Lilit
Holz, Carsten
Rieger, Andreas
Menzel, Matthias
Grond, Stefan
Soukup, Jens
Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title_full Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title_fullStr Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title_full_unstemmed Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title_short Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]
title_sort efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [isrctn62699180]
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297608/
https://www.ncbi.nlm.nih.gov/pubmed/16277715
http://dx.doi.org/10.1186/cc3767
work_keys_str_mv AT harutjunyanlilit efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180
AT holzcarsten efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180
AT riegerandreas efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180
AT menzelmatthias efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180
AT grondstefan efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180
AT soukupjens efficiencyof72hypertonicsalinehydroxyethylstarch20005versusmannitol15inthetreatmentofincreasedintracranialpressureinneurosurgicalpatientsarandomizedclinicaltrialisrctn62699180